目的 探讨妇科断红饮胶囊用于治疗放置依托孕烯皮下埋植避孕剂后异常子宫出血的临床疗效及安全性。方法 采用随机对照试验研究，选取2022年8月至2024年11月杭州市妇产科医院计划生育中心收治的60例放置依托孕烯皮下埋植避孕剂后出现异常子宫出血的患者，通过随机数字表法随机分为治疗组、对照组各30例。对照组除咨询安慰外不予以任何药物干预治疗，研究组加服妇科断红饮胶囊治疗。观察两组治疗的有效率、异常子宫出血阴道流血持续时间、异常子宫出血的复发率、皮下埋植避孕剂续用率、体内激素水平、子宫内膜厚度情况，并进行安全性评价。结果 研究组临床治疗总有效率为86.67%，显著高于对照组3.33% （P<0.001）；用药后第1个月月经周期阴道流血天数中位数为5.5（4.0，10.0）d、用药后第2个月月经周期阴道流血天数中位数为5.0（4.0，10.0）d以及用药后第3个月月经周期阴道流血天数中位数为5.0（4.0，8.5）d，分别与对照组比较差异有统计学意义（均P<0.001）。治疗结束后3个月异常子宫出血复发率研究组为20.00%（对照组100.00%），随访后续皮下埋植避孕剂取出率研究组仅为36.67%（对照组96.67%），差异均有统计学意义（均P<0.001）。并发症发生率及其他不良事件发生率，研究组与对照组接近，差异均无统计学意义（均P>0.05）。结论 妇科断红饮胶囊治疗皮下埋植避孕剂后引起的异常子宫出血，临床疗效显著且用药安全。

Objective Observation of the clinical efficacy and safety of gynecological Duanhongyin capsules in the treatment of abnormal uterine bleeding after placement of subcutaneous implanted contraceptive with pregnene. Methods This study is a randomized controlled trial，using a numerical table method to randomly select 60 patients from the Family Planning Center of Hangzhou Obstetrics and Gynecology Hospital from August 2022 to November 2024 who experienced abnormal uterine bleeding after receiving subcutaneous implantation of etoposide contraceptive，divided into a treatment group and a control group，with 30 cases in each group.The control group did not receive any medication intervention treatment except for counseling and comfort. The research group added gynecological Duanhongyin capsules for treatment. Observe the effective rate of two treatment groups，the duration of abnormal uterine bleeding and vaginal bleeding，the recurrence rate of abnormal uterine bleeding，the continuation rate of subcutaneous implant contraception，hormone levels in the body，and endometrial thickness，and conduct safety evaluation. Results The total effective rate of clinical treatment in the research group was 86.67%，significantly higher than the control group's 3.33% （P<0.001）；The median number of vaginal bleeding days in the first month after medication was 5.5 （4.0，10.0），the median number of vaginal bleeding days in the second month after medication was 5.0 （4.0，10.0），and the median number of vaginal bleeding days in the third month after medication was 5.0 （4.0，8.5），all of which showed statistically significant differences compared to the control group （P<0.001）.The recurrence rate of abnormal uterine bleeding after 3 months of observation and treatment was 20.00% in the study group （100.00% in the control group），and the follow-up removal rate was only 36.67% in the study group （96.67% in the control group），with significant statistical differences （all P<0.001）. The incidence of complications and other adverse events was similar between the study group and the control group，with no statistically significant differences （all P>0.05）. Conclusion Gynecological Duanhongyin capsules have shown significant clinical efficacy and medication safety in treating abnormal uterine bleeding caused by subcutaneous implantation of contraceptive agents.